Novel indenoisoquinolines NSC 725776 and NSC 724998 produce persistent topoisomerase I cleavage complexes and overcome multidrug resistance

Cancer Research

Volumn 67, Issue 21, 2007, Pages 10397-10405

  Antony, Smitha ^a   Agama, Keli K ^a   Miao, Ze Hong ^a   Takagi, Kazutaka ^a   Wright, Mollie H ^a   Robles, Ana I ^a   Varticovski, Lyuba ^a   Nagarajan, Muthukaman ^b   Morrell, Andrew ^b   Cushman, Mark ^b   Pommier, Yves ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

^b PURDUE UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CAMPTOTHECIN DERIVATIVE; DNA TOPOISOMERASE INHIBITOR; HISTONE H2AX; INDENOISOQUINOLINE DERIVATIVE; NSC 724998; NSC 725776; PROTEIN P53; TUMOR MARKER; UNCLASSIFIED DRUG;

ANIMAL CELL; ANTINEOPLASTIC ACTIVITY; ARTICLE; CELL CYCLE ARREST; CELL CYCLE G2 PHASE; CELL CYCLE M PHASE; CELL CYCLE S PHASE; CONTROLLED STUDY; CYTOTOXICITY; DNA CLEAVAGE; DNA STRAND BREAKAGE; DRUG STRUCTURE; HUMAN; HUMAN CELL; MOUSE; MULTIDRUG RESISTANCE; NONHUMAN; PRIORITY JOURNAL;

ANIMALS; ANTINEOPLASTIC AGENTS; ATP-BINDING CASSETTE TRANSPORTERS; CELL CYCLE; CELL LINE, TUMOR; DNA; DNA TOPOISOMERASES, TYPE I; DRUG RESISTANCE, MULTIPLE; DRUG RESISTANCE, NEOPLASM; ENZYME INHIBITORS; HISTONES; HUMANS; INDENES; ISOQUINOLINES; NEOPLASM PROTEINS; P-GLYCOPROTEIN;

EID: 35948968756     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-07-0938     Document Type: Article

References (50)

1. Hsiang YH, Hertzberg R, Hecht S, Liu LF. Camptothecin induces protein-linked DNA breaks via mammalian DNA topoisomerase I. J Biol Chem 1985;260: 14873-8.
2. Nitiss J, Wang JC. DNA topoisomerase-targeting antitumor drugs can be studied in yeast. Proc Natl Acad Sci U S A 1988;85:7501-5.
3. Froelich-Ammon SJ, Osheroff N. Topoisomerase poisons: harnessing the dark side of enzyme mechanism. J Biol Chem 1995;270:21429-32.
4. Pommier Y. Topoisomerase I inhibitors: camptothecins and beyond. Nat Rev Cancer 2006;6:789-802.
5. Covey JM, Jaxel C, Kohn KW, Pommier Y. Protein-linked DNA strand breaks induced in mammalian cells by camptothecin, an inhibitor of topoisomerase I. Cancer Res 1989;49:5016-22.
6. Burke TG, Mi Z. The structural basis of camptothecin interactions with human serum albumin: impact on drug stability. J Med Chem 1994;37:40-6.
7. Staker BL, Hjerrild K, Feese MD, Behnke CA, Burgin AB, Jr., Stewart L. The mechanism of topoisomerase I poisoning by a camptothecin analog. Proc Natl Acad Sci U S A 2002;99:15387-92.
8. Brangi M, Litman T, Ciotti M, et al. Camptothecin resistance: role of the ATP-binding cassette (ABC), mitoxantrone-resistance half-transporter (MXR), and potential for glucuronidation in MXR-expressing cells. Cancer Res 1999;59:5938-46.
9. Kohlhagen G, Paull KD, Cushman M, Nagafuji P, Pommier Y. Protein-linked DNA strand breaks induced by NSC 314622, a novel noncamptothecin topoisomerase I poison. Mol Pharmacol 1998;54:50-8.
10. Cushman M, Jayaraman M, Vroman JA, et al. Synthesis of new indeno[1,2-c]isoquinolines: cytotoxic non-camptothecin topoisomerase I inhibitors. J Med Chem 2000;43:3688-98.
11. Fox BM, Xiao X, Antony S, et al. Design, synthesis, and biological evaluation of cytotoxic 11-alkenylindenoisoquinoline topoisomerase I inhibitors and indenoisoquinoline-camptothecin hybrids. J Med Chem 2003;46:3275-82.
12. Strumberg D, Pommier Y, Paull K, Jayaraman M, Nagafuji P, Cushman M. Synthesis of cytotoxic indenoisoquinoline topoisomerase I poisons. J Med Chem 1999;42:446-57.
13. Antony S, Kohlhagen G, Agama K, et al. Cellular topoisomerase I inhibition and antiproliferative activity by MJ-III-65 (NSC 706744), an indenoisoquinoline topoisomerase I poison. Mol Pharmacol 2005;67:523-30.
14. Ioanoviciu A, Antony S, Pommier Y, Staker BL, Stewart L, Cushman M. Synthesis and mechanism of action studies of a series of norindenoisoquinoline topoisomerase I poisons reveal an inhibitor with a flipped orientation in the ternary DNA-enzyme-inhibitor complex as determined by X-ray crystallographic analysis. J Med Chem 2005;48:4803-14.
15. Marchand C, Antony S, Kohn KW, et al. A novel norindenoisoquinoline structure reveals a common interfacial inhibitor paradigm for ternary trapping of the topoisomerase I-DNA covalent complex. Mol Cancer Ther 2006;5:287-95.
16. Staker BL, Feese MD, Cushman M, et al. Structures of three classes of anticancer agents bound to the human topoisomerase I-DNA covalent complex. J Med Chem 2005;48:2336-45.
17. Rajendra R, Gounder MK, Saleem A, et al. Differential effects of the breast cancer resistance protein on the cellular accumulation and cytotoxicity of 9-amino-camptothecin and 9-nitrocamptothecin. Cancer Res 2003;63:3228-33.
18. Antony S, Jayaraman M, Laco G, et al. Differential induction of topoisomerase I-DNA cleavage complexes by the indenoisoquinoline MJ-III-65 (NSC 706744) and camptothecin: base sequence analysis and activity against camptothecin-resistant topoisomerases I. Cancer Res 2003;63:7428-35.
19. Tanizawa A, Kohn KW, Kohlhagen G, Leteurtre F, Pommier Y. Differential stabilization of eukaryotic DNA topoisomerase I cleavable complexes by camptothecin derivatives. Biochemistry 1995;34:7200-6.
20. Huang X, Traganos F, Darzynkiewicz Z. DNA damage induced by DNA topoisomerase I- and topoisomerase II-inhibitors detected by histone H2AX phosphorylation in relation to the cell cycle phase and apoptosis. Cell Cycle 2003;2:614-9.
21. Furuta T, Takemura H, Liao ZY, et al. Phosphorylation of histone H2AX and activation of Mre11, Rad50, and Nbs1 in response to replication-dependent DNA double-strand breaks induced by mammalian DNA topoisomerase I cleavage complexes. J Biol Chem 2003; 278:20303-12.
22. Gorgoulis VG, Vassiliou LV, Karakaidos P, et al. Activation of the DNA damage checkpoint and genomic instability in human precancerous lesions. Nature 2005; 434:907-13.
23. Kummar S, Kinders R, Rubinstein L, et al. Compressing drug development timelines in oncology using phase '0' trials. Nat Rev Cancer 2007;7:131-9.
24. Cushman M, Cheng L. A stereoselective oxidation by thionyl chloride leading to the indeno[1,2-c] isoquinoline system. J Org Chem 1978;43:3781.
25. Nagarajan M, Morrell A, Ioanoviciu A, et al. Synthesis and evaluation of indenoisoquinoline topoisomerase I inhibitors substituted with nitrogen heterocycles. J Med Chem 2006;49:6283-9.
26. Antony S, Agama KK, Miao ZH, et al. Bisindenoisoquinoline bis-1,3-{(5,6-dihydro-5,11-diketo-11H-indeno[1,2-c]isoquinoline) -6-propylamino}propane bis(trifluoroacetate) (NSC 727357), a DNA intercalator and topoisomerase inhibitor with antitumor activity. Mol Pharmacol 2006;70:1109-20.
27. Kohn KW. DNA filter elution: a window on DNA damage in mammalian cells. Bioessays 1996;18:505-13.
28. Shaw JL, Blanco J, Mueller GC. Simple procedure for isolation of DNA, RNA and protein fractions from cultured animal cells. Anal Biochem 1975;65:125-31.
29. Subramanian D, Kraut E, Staubus A, Young DC, Muller MT. Analysis of topoisomerase I/DNA complexes in patients administered topotecan. Cancer Res 1995;55: 2097-103.
30. Sordet O, Khan QA, Plo I, et al. Apoptotic topoisomerase I-DNA complexes induced by staurosporine-mediated oxygen radicals. J Biol Chem 2004;279:50499-504.
31. Mattern MR, Hofmann GA, McCabe FL, Johnson RK. Synergistic cell killing by ionizing radiation and topoisomerase I inhibitor topotecan (SK&F 104864). Cancer Res 1991;51:5813-6.
32. Miao ZH, Player A, Shankavaram U, et al. Nonclassical functions of human topoisomerase I: genome-wide and pharmacological analyses. Cancer Res 2007;67: 8752-61.
33. Robey RW, Honjo Y, Morisaki K, et al. Mutations at amino-acid 482 in the ABCG2 gene affect substrate and antagonist specificity. Br J Cancer 2003;89:1971-8.
34. Pourquier P, Takebayashi Y, Urasaki Y, Gioffre C, Kohlhagen G, Pommier Y. Induction of topoisomerase I cleavage complexes by 1-β-D- arabinofuranosylcytosine (ara-C) in vitro and in ara-C-treated cells. Proc Natl Acad Sci U S A 2000;97:1885-90.
35. Kohn KW, Shao RG, Pommier Y. How do drug-induced topoisomerase I-DNA lesions signal to the molecular interaction network that regulates cell cycle checkpoints, DNA replication, and DNA repair? Cell Biochem Biophys 2000;33:175-80.
36. Tanizawa A, Fujimori A, Fujimori Y, Pommier Y. Comparison of topoisomerase I inhibition, DNA damage, and cytotoxicity of camptothecin derivatives presently in clinical trials. J Natl Cancer Inst 1994;86: 836-42.
37. Li G, Bush JA, Ho VC. p53-dependent apoptosis in melanoma cells after treatment with camptothecin. J Invest Dermatol 2000;114:514-9.
38. Shao RG, Cao CX, Shimizu T, O'Connor PM, Kohn KW, Pommier Y. Abrogation of an S-phase checkpoint and potentiation of camptothecin cytotoxicity by 7-hydroxystaurosporine (UCN-01) in human cancer cell lines, possibly influenced by p53 function. Cancer Res 1997;57:4029-35.
39. Hoki Y, Fujimori A, Pommier Y. Differential cytotoxicity of clinically important camptothecin derivatives in P-glycoprotein-overexpressing cell lines. Cancer Chemother Pharmacol 1997;40:433-8.
40. Garcia-Carbonero R, Supko JG. Current perspectives on the clinical experience, pharmacology, and continued development of the camptothecins. Clin Cancer Res 2002;8:641-61.
41. Wall ME, Wani MC. Camptothecin and taxol: discovery to clinic - thirteenth Bruce F. Cain Memorial Award Lecture. Cancer Res 1995;55:753-60.
42. Garst J. Safety of topotecan in the treatment of recurrent small-cell lung cancer and ovarian cancer. Expert Opin Drug Saf 2007;6:53-62.
43. Fuchs C, Mitchell EP, Hoff PM. Irinotecan in the treatment of colorectal cancer. Cancer Treat Rev 2006; 32:491-503.
44. Jayaraman M, Fox BM, Hollingshead M, Kohlhagen G, Pommier Y, Cushman M. Synthesis of new dihydroindeno[1,2-c]isoquinoline and indenoisoquinolinium chloride topoisomerase I inhibitors having high in vivo anticancer activity in the hollow fiber animal model. J Med Chem 2002;45:242-9.
45. Morrell A, Antony S, Kohlhagen G, Pommier Y, Cushman M. Synthesis of nitrated indenoisoquinolines as topoisomerase I inhibitors. Bioorg Med Chem Lett 2004;14:3659-63.
46. Nagarajan M, Morrell A, Fort BC, et al. Synthesis and anticancer activity of simplified indenoisoquinoline topoisomerase I inhibitors lacking substituents on the aromatic rings. J Med Chem 2004;47:5651-61.
47. Nagarajan M, Xiao X, Antony S, Kohlhagen G, Pommier Y, Cushman M. Design, synthesis, and biological evaluation of indenoisoquinoline topoisomerase I inhibitors featuring polyamine side chains on the lactam nitrogen. J Med Chem 2003;46:5712-24.
48. Xiao X, Antony S, Kohlhagen G, Pommier Y, Cushman M. Design, synthesis, and biological evaluation of cytotoxic 11-aminoalkenylindenoisoquinoline and 11-diaminoalkenylindenoisoquinoline topoisomerase I inhibitors. Bioorg Med Chem 2004;12:5147-60.
49. Jaxel C, Capranico G, Kerrigan D, Kohn KW, Pommier Y. Effect of local DNA sequence on topoisomerase I cleavage in the presence or absence of camptothecin. J Biol Chem 1991;266:20418-23.
50. Rogakou EP, Pilch DR, Orr AH, Ivanova VS, Bonner WM. DNA double-stranded breaks induce histone H2AX phosphorylation on serine 139. J Biol Chem 1998;273: 5858-68.